kyron.bio Funding News -Paris-Based Biotech kyron.bio Raises €5.5M Funding

Kyron.bio is working to improve biologic drug development by controlling sugar molecules (glycans) on the surface of drugs. This helps reduce side effects and make treatments more effective.

The €5.5M funding will support platform development, team expansion, and preclinical research.

The funding also supports the launch of kyron.bio’s EIC Transition project, backed by the European Innovation Council.

Read Also - Delft-based medtech startup STIL Secures €2M Funding

Kyron.bio is changing the way medicines are made by using glycans—natural sugar structures—to improve treatments. The company plans to team up with pharmaceutical companies to develop better drugs.

Kyron.bio focuses on antibody therapeutics, which are drugs that help the immune system fight diseases like cancer and autoimmune disorders.

One big problem with these drugs is that the body can see them as foreign and attack them. This reduces how well the drug works and can be dangerous for patients, especially with long-term use.

This issue also makes it harder for new drugs to succeed in early clinical trials, where safety is the top priority. As drug design becomes more advanced, this challenge is becoming even more common.

To solve this, Kyron.bio has created a platform that controls N-glycosylation—how cells attach glycans to the drug’s surface. Normally, this process produces mixed structures that may cause immune reactions or weaken the drug.

Kyron.bio’s solution uses specific glycans to avoid these problems. It’s built to work smoothly with current drug manufacturing systems.

Kyron.bio uses two main technologies to improve antibody drugs.

First, they have created special cell lines by modifying Chinese Hamster Ovary (CHO) cells. This gives them full control over how glycans (sugar structures) are added during drug production.

Second, they have a glycan-engineering toolbox that lets them adjust the antibodies themselves. This helps reduce immune reactions, boosts performance, and creates new intellectual property.

Together, these technologies give Kyron.bio over 97% consistency in glycan structures—better than standard methods. This high level of control helps develop stronger, longer-lasting antibody therapies that avoid immune attacks and accurately target diseases.

Kyron.bio helps pharmaceutical companies create new types of monoclonal antibodies, which are special medicines. These medicines can be very complex and target several things at once, but this can sometimes cause the immune system to attack them.

Kyron.bio’s technology works to lower this risk.

For long-term illnesses like autoimmune diseases, their platform helps patients keep getting treatment without their bodies stopping the medicine from working.

In cancer treatment, the technology increases the chances that new drugs pass early safety tests in clinical trials.

Because treatments are becoming more complex and often need to be taken for a long time, the immune system attacking these medicines is a bigger problem.

Kyron.bio’s technology aims to solve this problem, helping more patients get effective treatments and keeping those treatments working longer.

It also hopes to create new treatment options for patients.

Dr. Emilia McLaughlin, CEO & Founder of kyron.bio, says, “To date, glycans have been massively under-exploited, limiting their potential in drug design. By achieving comprehensive control over glycosylation in a fully scalable manner, we have unlocked the possibility to use precision glycosylation in drug design.”

“This transforms glycans into a design tool for the first time, opening up new treatment avenues for patients. Securing this fundraising round brings us closer to our goal of delivering precision glycan-engineered therapeutics to patients.”

Dr. McLaughlin studied single-cell organisms during her PhD at Institut Pasteur Paris. Her research helped shape how kyron.bio creates new drugs. With her guidance, the company developed a new, protected method that can be scaled up to solve tricky problems in designing medicines.

HCVC is a venture capital firm that invests in new deeptech startups in Europe and the US. They help founders working in areas like biotech, defense, AI infrastructure, robotics, climate, and space. They have offices in Paris, London, and the Bay Area.

Speaking on the investment in kryon.bio, Alexis Houssou, Founder & Managing Partner at HCVC, says, “kyron.bio’s technology bridges a massive gap in therapeutics design. Their breakthrough in glycan control could shift the paradigm for antibody therapies, and we’re proud to support their vision.”

About kyron.bio

Founded in 2022, Kyron.bio is a women-led biotech company based in Paris. They develop new therapeutic proteins by carefully controlling the sugar patterns on their surfaces. This technique, called "glycan engineering," helps make medicines safer and more effective, especially monoclonal antibodies.